CN113577261B - Preparation and application of recombinant protein Bfra nano-particles - Google Patents
Preparation and application of recombinant protein Bfra nano-particles Download PDFInfo
- Publication number
- CN113577261B CN113577261B CN202110882135.5A CN202110882135A CN113577261B CN 113577261 B CN113577261 B CN 113577261B CN 202110882135 A CN202110882135 A CN 202110882135A CN 113577261 B CN113577261 B CN 113577261B
- Authority
- CN
- China
- Prior art keywords
- bfra
- plga
- paratuberculosis
- protein
- recombinant protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 36
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims abstract description 22
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims description 11
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract description 19
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 claims abstract description 15
- 208000026681 Paratuberculosis Diseases 0.000 claims abstract description 13
- 102000036639 antigens Human genes 0.000 claims abstract description 13
- 108091007433 antigens Proteins 0.000 claims abstract description 13
- 239000000839 emulsion Substances 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 13
- 230000009465 prokaryotic expression Effects 0.000 claims abstract description 6
- 241000588724 Escherichia coli Species 0.000 claims abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 229960005486 vaccine Drugs 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 210000003022 colostrum Anatomy 0.000 claims description 8
- 235000021277 colostrum Nutrition 0.000 claims description 8
- 239000004005 microsphere Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 238000004945 emulsification Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000005457 ice water Substances 0.000 claims description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 3
- 229930027917 kanamycin Natural products 0.000 claims description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 3
- 229960000318 kanamycin Drugs 0.000 claims description 3
- 229930182823 kanamycin A Natural products 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 230000003698 anagen phase Effects 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 241001052560 Thallis Species 0.000 claims 2
- 238000005520 cutting process Methods 0.000 claims 2
- 238000004140 cleaning Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 238000009210 therapy by ultrasound Methods 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 12
- 230000003053 immunization Effects 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 2
- 239000002861 polymer material Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000012460 protein solution Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 241000186367 Mycobacterium avium Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- -1 iron ions Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OWMCODAXNFNLCU-UHFFFAOYSA-N 2-[[2-(1h-imidazol-5-yl)ethylamino]methyl]phenol Chemical compound OC1=CC=CC=C1CNCCC1=CN=CN1 OWMCODAXNFNLCU-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101000894412 Mycolicibacterium paratuberculosis (strain ATCC BAA-968 / K-10) Bacterioferritin Proteins 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 108010027375 bacterioferritin Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The application provides a method for prokaryotic expression of mycobacterium paratuberculosis antigen protein Bfra, a method for preparing recombinant protein Bfra-PLGA nano particles and application thereof in preventing paratuberculosis. The recombinant protein Bfra was expressed by E.coli prokaryotic by amplifying the Mycobacterium paratuberculosis MAP1595 gene, ligating it to pET-30a (+). And encapsulating the obtained recombinant protein Bfra into a high polymer material PLGA by an improved multiple emulsion volatilization method to prepare the nano-particle Bfra-PLGA. The prepared Bfra-PLGA nano particles are used for immunizing mice, and have good protection effects at 8 weeks and 12 weeks after the infection of the mycobacterium paratuberculosis.
Description
Technical Field
The application belongs to the field of vaccines, and particularly provides a method for prokaryotic expression of mycobacterium paratuberculosis antigen protein Bfra, a method for preparing recombinant protein Bfra-PLGA nano particles and application of the recombinant protein Bfra-PLGA nano particles in preventing paratuberculosis.
Background
The paratuberculosis is a ruminant irreversible and chronic consumable disease caused by mycobacterium paratuberculosis (Mycobacterium avium subspecies paratuberculosis, MAP) of mycobacterium avium subspecies, the incubation period of the disease is longer and can reach 2-5 years, the main symptoms are chronic proliferative enteritis, and symptoms such as fold, weight loss, milk yield and fertility decline are formed along with intractable diarrhea and intestinal mucosa thickening, and the animal can die due to chronic failure caused by serious illness. The paratuberculosis is considered as one of the most serious diseases affecting the dairy industry, and in recent years, the onset condition of the paratuberculosis in China is rapidly increased, and great impact is brought to the dairy industry and dairy industry in China. However, the whole-cell inactivated vaccine of MAP is only available in the market at present, but can not completely block the infection of paratuberculosis and has serious side effects, so that the injection site forms a lump. Therefore, the development of a novel subunit vaccine has important significance for the prevention and control of the mycobacterium paratuberculosis.
Bfra, also known as cytochrome b1, is the primary iron storage protein of bacteria. Antigen D of Mycobacterium paratuberculosis is identified as Bfra and is capable of enriching, managing and storing iron ions, maintaining the balance of intracellular iron ions of MAP and enhancing the survival ability of MAP. Bfra is currently widely reported as a T lymphocyte antigen that induces IFN-gamma to be expressed in large amounts and lymphocyte proliferation. In addition, the DNA vaccine for encoding Bfra and the recombinant Bfra protein can induce obvious humoral immune response when used for immunizing mice, and further has a certain protective effect on the mice.
PLGA is a degradable high molecular organic compound formed by randomly polymerizing two monomers of lactic acid and glycolic acid, and has the advantages of no toxicity, good biocompatibility and capability of forming capsules and films. PLGA has been approved by the food and drug administration (Food and Drug Administration, FDA) as a delivery vehicle for vaccines and drugs due to its excellent safety in the human and animal body.
Disclosure of Invention
The applicant tried to prepare PLGA particles with various antigens/vaccines, found that only a part of the antigens/vaccines was suitable to prepare the form (e.g., the preparation of the MAP antigen HBHA into PLGA particles was not effective), studied to prepare nanoparticles for preventing paratuberculosis using PLGA-entrapped recombinant mycobacterium paratuberculosis antigen protein Bfra, and confirmed that they can be used as a novel nano-subunit paratuberculosis vaccine.
In one aspect, the application provides a recombinant protein Bfra nanoparticle, which is characterized in that the recombinant protein Bfra nanoparticle is PLGA-entrapped recombinant antigen protein Bfra of mycobacterium paratuberculosis.
Further, the nucleic acid sequence of the mycobacterium paratuberculosis antigen protein Bfra is SEQ ID NO.1.
Further, the nanoparticle preparation process includes: the preparation method comprises the steps of protein recombinant expression and nanoparticle preparation, wherein the nanoparticle preparation step comprises the steps of dripping a protein solution into PLGA ethyl acetate solution, preparing colostrum, preparing pre-multiple emulsion, preparing multiple emulsion and freeze-drying.
Further, the concentration of the protein solution is 2-4mg/mL when the protein solution is added dropwise to the PLGA ethyl acetate solution.
Further, the nanoparticle preparation step specifically comprises:
1) Weighing 0.2g of PLGA, dissolving in 4.5mL of ethyl acetate, and shaking and mixing until the PLGA is completely dissolved;
2) Extracting 0.5mL of target protein solution with a syringe, dripping the target protein solution into the ethyl acetate solution prepared in the previous step to form micro-droplets, and then placing the micro-droplets into ice water;
3) Preparing colostrum: performing ultrasonic emulsification on the solution prepared in the second step under ice bath condition, wherein the ultrasonic condition is 300W, the total time is 4min, the working is 2s, and the operation is stopped for 3s;
4) Preparing pre-compound emulsion: pouring the prepared colostrum into 10mL of 1% PVA solution, performing ultrasonic emulsification under ice bath condition, wherein the ultrasonic condition is 300W, the total time is 6min, working is 2s, and stopping for 3s;
5) Pouring the prepared pre-compound emulsion into 10mL of 0.5% PVA solution to prepare compound emulsion; stirring at 300-400rpm at room temperature for 4h to volatilize the oil phase;
6) Centrifuging the obtained nanoparticle solution in a high-speed refrigerated centrifuge for 3min under 12000r/min, removing supernatant, adding distilled water, washing for 2 times, removing supernatant, and storing at 4deg.C for several days or vacuum lyophilizing at-80deg.C to obtain microsphere powder.
Further, the recombinant expression steps of the protein are as follows:
bfra was added with 5'EcoRI and 3' HindIII at both ends of the gene sequence, ligated to prokaryotic expression vector pET-30a (+) by double digestion, and transformed into E.coli competent cell BL21 (DE 3), the bacteria were cultured with LB medium containing kanamycin at a final concentration of 50. Mu.g/mL to a logarithmic growth phase of OD600nm of 0.6-0.8, IPTG at a final concentration of 1mM was added, shaking table at 30℃and 160rpm, induced expression was performed for 4h,4℃and centrifugation at 8000rpm for 3min to collect the cells, and washed twice with pre-chilled PBS, the cells were resuspended and sonicated with PBS, lysed, and centrifuged at 10000rpm for 10min to obtain a lysate. Purifying the cleavage supernatant by Ni column affinity chromatography to obtain recombinant protein Bfra.
On the other hand, the application provides application of the recombinant protein Bfra nano-particles in preparing paratuberculosis vaccines.
On the other hand, the application provides a paratuberculosis vaccine which is characterized by comprising the recombinant protein Bfra nano-particles and auxiliary materials.
Further, the vaccine can reduce the bacterial load of the vaccinated subjects after infection.
Further, the vaccine can promote TNF-alpha, IL-10, IFN-gamma and antibody IgG secretion after infection of an vaccinated subject.
The Bfra protein sequence in the present application is not limited to SEQ ID NO.1, and Bfra protein sequences having differences in nucleic acid sequence and even amino acid sequence of other MAP may be used.
The nanoparticles/vaccines of the present application are preferably used by injection, but it is not excluded that the nanoparticles/vaccines are administered orally, nasally, etc. after selection of the appropriate carrier and formulation.
Adjuvants of the present application may be selected from known or developed varieties according to conventional knowledge in the vaccine art by those skilled in the art, including but not limited to adjuvants, solvents, co-solvents, buffers, antioxidants, preservatives
Drawings
FIG. 1 shows purified recombinant protein Bfra by SDS-PAGE and Western blot;
FIG. 2 is a representation of Bfra-PLGA nanoparticles;
FIG. 3 is an immune evaluation of nanoparticles;
FIG. 4 shows liver load of mice.
Detailed Description
EXAMPLE 1 construction of prokaryotic expression vectors for Bfra protein
The MAP1595 gene of the K-10 standard strain of Mycobacterium paratuberculosis was amplified as follows:
ATGCAAGGGGATCCGGAAGTTTTGCGTCTGCTCAACGAGCAGCTGACCAGCGAACTCACCGCGATCAACCAATACTTCCTGCACTCCAAGATGCAGGACAACTGGGGGTTCACCGAGTTAGCTGAGCACACCCGGGCCGAGTCCTTCGACGAGATGCGCCACGCCGAGGCGATCACCGACCGCATCCTGCTGCTCGACGGGTTGCCGAACTATCAGCGCCTGTTCTCGCTGCGCATCGGCCAGACGCTGCGCGAGCAGTTCGAGGCCGACCTGGCCATCGAATACGAGGTGATGGACCGGCTCAAGCCGGCCATCATCCTGTGCCGGGAGAAGCAGGACTCCACCACCGCCACGCTTTTCGAGCAGATCGTCGCCGACGAGGAAAAGCACATCGACTACCTGGAGACGCAGCTGGAGTTGATGGACAAGCTGGGCGTGGAGCTCTACTCGGCGCAGTGCGTGTCGCGGCCACCGAGC(SEQ ID NO.1)。
the restriction sites 5 '(EcoRI) and 3' (HindIII) were added to both ends of the above gene sequence, ligated to the prokaryotic expression vector pET-30a (+) by double restriction, and transformed into E.coli competent cells BL21 (DE 3), the bacteria were cultured in LB medium containing kanamycin (final concentration of 50. Mu.g/mL) to logarithmic phase (OD 600nm of 0.6-0.8), IPTG (final concentration of 1 mM) was added, shaking table at 30℃and 160rpm, induced expression was performed for 4h, centrifugation at 8000rpm for 3min, and cells were collected by washing twice with pre-chilled PBS, resuspended and sonicated with PBS, lysed, and centrifuged at 10000rpm for 10min to obtain a lysate. Purifying the cleavage supernatant by Ni column affinity chromatography to obtain recombinant protein Bfra.
Purified Bfra protein was subjected to SDS-PAGE gel electrophoresis and coomassie blue staining, which showed that purified Bfra was more than 90% pure (fig. 1A), and Western blot identification was performed with MAP positive serum from mice infected, which showed that a single band was visible on NC membrane, conforming to the expected size (fig. 1B).
EXAMPLE 2 preparation of recombinant protein Bfra-PLGA nanoparticles
1) Weighing 0.2g of PLGA, dissolving in 4.5mL of ethyl acetate, shaking and mixing until the PLGA is completely dissolved, and filtering to remove precipitate;
2) Extracting 0.5mL of a protein solution (2-4 mg/mL, and a plurality of concentration experiments show that the excessive protein concentration is easy to cause the precipitation of nano particles) by using a syringe, dripping the solution into the ethyl acetate solution prepared in the previous step to form micro-droplets, and then placing the micro-droplets into ice water;
3) Preparing colostrum: performing ultrasonic emulsification on the solution prepared in the second step under ice bath condition, wherein the ultrasonic condition is 300W, the total time is 4min, the working is 2s, and the operation is stopped for 3s;
4) Preparing pre-compound emulsion: pouring the prepared colostrum into 10mL of 1% PVA solution, performing ultrasonic emulsification under ice bath condition, wherein the ultrasonic condition is 300W, the total time is 6min, working is 2s, and stopping for 3s;
5) Pouring the prepared pre-compound emulsion into 10mL of 0.5% PVA solution to prepare compound emulsion; stirring at 300-400rpm at room temperature for 4h to volatilize the oil phase;
6) Centrifuging the obtained nanoparticle solution in a high-speed refrigerated centrifuge for 3min under 12000r/min, removing supernatant, adding distilled water, washing for 2 times, removing supernatant, and storing at 4deg.C for several days or vacuum lyophilizing at-80deg.C to obtain microsphere powder.
EXAMPLE 3 characterization of recombinant protein Bfra-PLGA nanoparticles
And dispersing a proper amount of microsphere powder with a small amount of deionized water, uniformly spreading on a corresponding metal plate of the instrument, drying at normal temperature, spraying gold, and observing the morphology of the microspheres under a scanning electron microscope. Taking a small amount of microsphere powder, re-dissolving with deionized water to uniformly disperse the microsphere powder, placing the microsphere powder into a dynamic optical particle analyzer according to the specification, and analyzing data by using Malvern Instrument software.
As shown in FIG. 2, the average particle size of the prepared Bfra-PLGA nanoparticles was about 230nm, and the potential was-21.2 mV. The nanoparticle encapsulation efficiency was calculated to be 81% after measurement using an ultraviolet spectrophotometer. The scanning electron microscope result shows that Bfra-PLGA nano particles have uniform size and are spherical with smoother surfaces.
EXAMPLE 4 evaluation of the immunogenicity and protective Properties of recombinant protein Bfra-PLGA nanoparticles
The C57BL/6 mice were randomly divided into 4 groups of 15 animals each, PBS group (PBS), bfra group (Bfra), blank pellet group (PBS-PLGA) and Bfra-PLGA nanoparticle group (Bfra-PLGA), respectively. The immunization mode is as follows: injecting 100 mu l PBS/1 into PBS group, injecting 100 mu l (100 mu g/1) of recombinant protein Bfra into Bfra group, injecting 100 mu l PBS-PLGA into blank particle group (PBS redissolution, 5 mg/1), injecting 100 mu l Bfra-PLGA into Bfra-PLGA group (PBS redissolution, 5 mg/1); each group was immunized three times, two weeks apart, and after the last immunization, 5 mice were randomly selected for detection of relevant immune indicators. The toxin attacking mode is as follows: two weeks after the last immunization, each group of mice was intraperitoneally injected with 100 μl of 10 8 CFU/MAP only (2015 WD-1 strain); after 8 weeks of virus attack, 5 mice are randomly selected for each group to carry out subsequent detection by taking section samples; after 12 weeks of challenge, 5 mice per group were randomly selected for follow-up testing by dissecting samples.
The results in FIG. 3 show that Bfra-PLGA significantly promoted secretion of cytokines TNF- α, IL-10 and antibody IgG in serum (FIG. 3A, B, C) and IFN- γ in spleen cell supernatant (FIG. 3D).
The results of detecting the liver bacterial load of the mice after MAP challenge for 8 weeks (figure 4) show that compared with the PBS group, the liver bacterial load of the Bfra-PLGA group is obviously reduced (figure 4A); the results of detecting the liver bacterial load of the mice after MAP challenge for 12 weeks show that compared with the PBS group, the PBS-PLGA group, the Bfra group and the Bfra-PLGA group have obviously reduced liver bacterial load of the mice, and the Bfra-PLGA group has most obvious reduction.
Sequence listing
<110> Chinese university of agriculture
<120> preparation and application of recombinant protein Bfra nanoparticle
<130> aaaaa
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 477
<212> DNA
<213> artificial sequence
<400> 1
atgcaagggg atccggaagt tttgcgtctg ctcaacgagc agctgaccag cgaactcacc 60
gcgatcaacc aatacttcct gcactccaag atgcaggaca actgggggtt caccgagtta 120
gctgagcaca cccgggccga gtccttcgac gagatgcgcc acgccgaggc gatcaccgac 180
cgcatcctgc tgctcgacgg gttgccgaac tatcagcgcc tgttctcgct gcgcatcggc 240
cagacgctgc gcgagcagtt cgaggccgac ctggccatcg aatacgaggt gatggaccgg 300
ctcaagccgg ccatcatcct gtgccgggag aagcaggact ccaccaccgc cacgcttttc 360
gagcagatcg tcgccgacga ggaaaagcac atcgactacc tggagacgca gctggagttg 420
atggacaagc tgggcgtgga gctctactcg gcgcagtgcg tgtcgcggcc accgagc 477
Claims (1)
1. An application of recombinant protein Bfra nano-particles in preparing paratuberculosis vaccines, wherein the recombinant protein Bfra nano-particles are PLGA-entrapped recombinant antigen protein Bfra of paratuberculosis mycobacteria; the nucleic acid sequence of the recombinant antigen protein Bfra of the mycobacterium paratuberculosis is SEQ ID NO.1;
the preparation process of the recombinant protein Bfra nano-particles comprises the following steps:
1) Weighing 0.2g of PLGA, dissolving in 4.5mL of ethyl acetate, and shaking and mixing until the PLGA is completely dissolved;
2) Extracting 0.5mL of 2-4mg/mL of recombinant antigen protein Bfra solution of mycobacterium paratuberculosis by using a syringe, dripping the solution obtained in the step 1) to form micro-droplets, and then placing the micro-droplets in ice water;
3) Preparing colostrum: performing ultrasonic emulsification on the solution obtained in the step 2) under ice bath conditions, wherein the ultrasonic conditions are 300W, the total time is 4min, the operation is 2s, and the operation is stopped for 3s to obtain colostrum;
4) Preparing pre-compound emulsion: pouring the colostrum obtained in the step 3) into 10mL of 1% PVA solution, performing ultrasonic emulsification under ice bath condition, wherein the ultrasonic condition is 300W, the total time is 6min, working is 2s, and stopping for 3s to obtain pre-compound emulsion;
5) Pouring the pre-compound emulsion obtained in the step 4) into 10mL of 0.5% PVA solution to prepare compound emulsion; stirring at 300-400rpm at room temperature for 4h, volatilizing the oil phase to obtain nanoparticle solution;
6) Centrifuging the nanoparticle solution obtained in the step 5) in a high-speed refrigerated centrifuge for 3min under the centrifugation condition of 12000r/min, discarding the supernatant, adding distilled water for washing, cleaning for 2 times, discarding the supernatant, and preserving at 4 ℃ for a while or drying at-80 ℃ in a vacuum freeze dryer to obtain microsphere powder;
the expression steps of the recombinant antigen protein Bfra of the mycobacterium paratuberculosis are as follows:
adding enzyme cutting sites 5'EcoRI and 3' HindIII at two ends of Bfra gene with a nucleic acid sequence of SEQ ID NO.1, connecting to a prokaryotic expression vector pET-30a (+) through double enzyme cutting, converting into escherichia coli competent cells BL21 (DE 3), culturing bacteria to a logarithmic growth phase with OD600nm of 006-000 by using LB culture medium containing kanamycin with a final concentration of 50 mug/mL, adding IPTG with a final concentration of 1mM, shaking table at 30 ℃,160rpm, carrying out induced expression for 4h,4 ℃ at 0000rpm for 3min, collecting thalli, washing twice by precooling PBS, re-suspending thalli by PBS and carrying out ultrasonic treatment, lysing, centrifuging at 10000rpm for 10min, and obtaining a lysate; purifying the cleavage supernatant by Ni column affinity chromatography to obtain the recombinant antigen protein Bfra of the mycobacterium paratuberculosis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110882135.5A CN113577261B (en) | 2021-08-02 | 2021-08-02 | Preparation and application of recombinant protein Bfra nano-particles |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110882135.5A CN113577261B (en) | 2021-08-02 | 2021-08-02 | Preparation and application of recombinant protein Bfra nano-particles |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113577261A CN113577261A (en) | 2021-11-02 |
CN113577261B true CN113577261B (en) | 2023-10-31 |
Family
ID=78253995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110882135.5A Active CN113577261B (en) | 2021-08-02 | 2021-08-02 | Preparation and application of recombinant protein Bfra nano-particles |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113577261B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106729623A (en) * | 2016-12-29 | 2017-05-31 | 华东理工大学 | A kind of mPEG PLGA nano particles for containing restructuring anti-tumor protein TmSm and its preparation method and application |
CN110354098A (en) * | 2019-07-23 | 2019-10-22 | 中国农业大学 | The preparation and application of recombinant protein c FP-10 nano particle |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003202826B9 (en) * | 2002-01-11 | 2008-06-19 | Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. | Diagnostics and vaccines for mycobacterium paratuberculosis infections |
US20080187922A1 (en) * | 2006-10-19 | 2008-08-07 | Fudan University | Method of screening drug-resistance protein of mycobacterium tuberculosis |
US7670609B2 (en) * | 2007-11-27 | 2010-03-02 | Aeras Global Tb Vaccine Foundation | Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease |
-
2021
- 2021-08-02 CN CN202110882135.5A patent/CN113577261B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106729623A (en) * | 2016-12-29 | 2017-05-31 | 华东理工大学 | A kind of mPEG PLGA nano particles for containing restructuring anti-tumor protein TmSm and its preparation method and application |
CN110354098A (en) * | 2019-07-23 | 2019-10-22 | 中国农业大学 | The preparation and application of recombinant protein c FP-10 nano particle |
Non-Patent Citations (1)
Title |
---|
徐志超.鸡白痢沙门氏菌优势抗原细菌铁蛋白诱导产生IFN-β的分子机理.中国博士学位论文全文数据库农业科技辑.2016,(第8期),D050-124. * |
Also Published As
Publication number | Publication date |
---|---|
CN113577261A (en) | 2021-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5327873B2 (en) | Recombinant Helicobacter pylori oral vaccine and preparation method thereof | |
US11975060B2 (en) | Controlled release vaccines and methods of treating Brucella diseases and disorders | |
CN109125719B (en) | Immunogenic composition containing porcine circovirus type 3 and porcine circovirus type 2 antigens and application thereof | |
CN110354098B (en) | Preparation and application of recombinant protein CFP-10 nanoparticles | |
JPH06501478A (en) | Uveitis treatment | |
dong Zhu et al. | Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis | |
JP7005747B2 (en) | Porcine Circovirus Type 3 immunogenic composition, its preparation method and use | |
CN110559432B (en) | Eimeria acervulina nano subunit vaccine and preparation method and application thereof | |
CN114028559B (en) | Aluminum-manganese composite nanocrystalline and preparation method and application thereof | |
JP2019521095A (en) | Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterial infections | |
CN113456810A (en) | Novel anti-neocoronavirus therapeutic vaccine and preparation method and application thereof | |
CN110559431B (en) | Eimeria maxima nano subunit vaccine and preparation method and application thereof | |
RU2708393C1 (en) | Lyophilised antibacterial protein compositions | |
EP2231181A1 (en) | New vaccine for the treatment of mycobacterium related disorders | |
CN110777160B (en) | Preparation method of foot-and-mouth disease virus-like particle antigen, foot-and-mouth disease virus-like particle antigen prepared by same and application thereof | |
CN113577261B (en) | Preparation and application of recombinant protein Bfra nano-particles | |
EP3078677B1 (en) | Antigen chimera, antigen combination, vaccine, method of preparing same, and kit thereof | |
JP5495261B2 (en) | Shigella IPAD protein and its use as a Shigella infection vaccine | |
WO2019178687A1 (en) | A method for lyophilizing live vaccine strains of francisella tularensis | |
US11717566B2 (en) | Brucella canis vaccine for dogs | |
EP2838990A1 (en) | Recombinant mycobacterium encoding a heparin-binding hemagglutinin (hbha) fusion protein and uses thereof | |
KR101978865B1 (en) | Vaccine composition comprising PLGA encapsulated inactivated microbial cell and method for preparing the same | |
KR102390674B1 (en) | Vaccine Composition for Preventing Canine Adenovirus Type 2 Infection | |
CN114073762B (en) | Brucella bi-component vaccine containing Omp19 and VirB8 proteins | |
CN116115565A (en) | PLGA nanoemulsion and preparation method and application thereof in paratuberculosis vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |